🔴 Liquidia Technologies is trading 5% down with no clear company-specific catalyst identified

Liquidia Technologies is trading at $67.14, down -5.01%; no clear company-specific announcement explaining the September 30 decline surfaced in the available search results.

• The latest identified company release was the September 3 FDA Fast Track designation for YUTREPIA, which predates the move.
• Broader indices were higher, so the decline did not align with the supplied market direction. Biotech underperformed over September overall, but that does not establish the cause of the drop.